CN102711803B - 用于肠和肌肉恢复的glp‑2 - Google Patents

用于肠和肌肉恢复的glp‑2 Download PDF

Info

Publication number
CN102711803B
CN102711803B CN201080055259.6A CN201080055259A CN102711803B CN 102711803 B CN102711803 B CN 102711803B CN 201080055259 A CN201080055259 A CN 201080055259A CN 102711803 B CN102711803 B CN 102711803B
Authority
CN
China
Prior art keywords
glp
seq
amino acid
acid sequence
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080055259.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102711803A (zh
Inventor
D·阿泰
A·科德兰-雷松
I·科尔特赛-图拉兹
D·布勒耶
L·孔巴雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe dAssistance Technique pour Produits Nestle SA
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dAssistance Technique pour Produits Nestle SA, Institut National de la Recherche Agronomique INRA filed Critical Societe dAssistance Technique pour Produits Nestle SA
Publication of CN102711803A publication Critical patent/CN102711803A/zh
Application granted granted Critical
Publication of CN102711803B publication Critical patent/CN102711803B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080055259.6A 2009-10-07 2010-10-07 用于肠和肌肉恢复的glp‑2 Active CN102711803B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172398.1 2009-10-07
EP09172398A EP2311486A1 (en) 2009-10-07 2009-10-07 GLP-2 for use in intestine and muscle recovery
PCT/EP2010/065021 WO2011042501A2 (en) 2009-10-07 2010-10-07 The intestine and muscle recovery

Publications (2)

Publication Number Publication Date
CN102711803A CN102711803A (zh) 2012-10-03
CN102711803B true CN102711803B (zh) 2017-02-22

Family

ID=41611235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080055259.6A Active CN102711803B (zh) 2009-10-07 2010-10-07 用于肠和肌肉恢复的glp‑2

Country Status (11)

Country Link
US (1) US20120270786A1 (enExample)
EP (2) EP2311486A1 (enExample)
JP (1) JP5801814B2 (enExample)
CN (1) CN102711803B (enExample)
AU (1) AU2010305420B2 (enExample)
BR (1) BR112012009380A2 (enExample)
CA (1) CA2776964C (enExample)
DK (1) DK2485756T3 (enExample)
ES (1) ES2539917T3 (enExample)
IN (1) IN2012DN03187A (enExample)
WO (1) WO2011042501A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051814A1 (en) * 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
JP6325215B2 (ja) * 2013-08-29 2018-05-16 テルモ株式会社 栄養補給用冷菓
ES2960218T3 (es) * 2014-10-14 2024-03-01 Nestle Sa Mejora en la funcionalidad del músculo de hombres ancianos
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR102119188B1 (ko) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661123A (en) * 1995-01-17 1997-08-26 Nestec, Ltd. Enteral composition for malabsorbing patients
CN1244872A (zh) * 1996-04-12 2000-02-16 1149336安大略公司 胰高血糖素样肽－2的类似物
US20030207809A1 (en) * 1997-05-02 2003-11-06 Nps Allelix Corporation Methods of enhancing functioning of the large intestine
US20040052862A1 (en) * 2000-09-18 2004-03-18 Henriksen Dennis B. Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20040248782A1 (en) * 2001-02-16 2004-12-09 BRIDON Dominique P. Long lasting glucagon-like peptide2(glp-2)for the treatment of gastrointestinal diseases and disorders
US20060105954A1 (en) * 1995-04-14 2006-05-18 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO2008056155A1 (en) * 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
CA2223198A1 (en) * 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
ATE396738T1 (de) * 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
PL376223A1 (en) * 2002-10-14 2005-12-27 Novo Nordisk As Glucagon - like peptide - 2 variants
US20040115708A1 (en) * 2002-10-28 2004-06-17 Ardies C. Murray Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia
JP4699374B2 (ja) * 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ 安定なペプチド及びポリペプチドアナログ治療剤
JP5788631B2 (ja) * 2005-04-06 2015-10-07 ネステク ソシエテ アノニム グルコース制御およびインスリン作用を栄養的に改善するための方法および組成物
CN101365350A (zh) * 2006-01-09 2009-02-11 雀巢技术公司 应激患者的治疗

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661123A (en) * 1995-01-17 1997-08-26 Nestec, Ltd. Enteral composition for malabsorbing patients
US20060105954A1 (en) * 1995-04-14 2006-05-18 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
CN1244872A (zh) * 1996-04-12 2000-02-16 1149336安大略公司 胰高血糖素样肽－2的类似物
US20030207809A1 (en) * 1997-05-02 2003-11-06 Nps Allelix Corporation Methods of enhancing functioning of the large intestine
US20040052862A1 (en) * 2000-09-18 2004-03-18 Henriksen Dennis B. Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20040248782A1 (en) * 2001-02-16 2004-12-09 BRIDON Dominique P. Long lasting glucagon-like peptide2(glp-2)for the treatment of gastrointestinal diseases and disorders
WO2008056155A1 (en) * 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mucosal Adaptation to Enteral Nutrients Is Dependent on the Physiologic Actions of Glucagon-Like Peptide-2 in Mice;ERIC D. SHIN et.al.,;《GASTROENTEROLOGY》;20050531;第128卷;全文 *

Also Published As

Publication number Publication date
AU2010305420A1 (en) 2012-05-10
HK1173949A1 (en) 2013-05-31
EP2485756A2 (en) 2012-08-15
BR112012009380A2 (pt) 2021-06-22
ES2539917T3 (es) 2015-07-07
WO2011042501A3 (en) 2011-06-03
JP2013507341A (ja) 2013-03-04
AU2010305420B2 (en) 2015-03-19
US20120270786A1 (en) 2012-10-25
IN2012DN03187A (enExample) 2015-09-25
CN102711803A (zh) 2012-10-03
EP2485756B1 (en) 2015-05-20
EP2311486A1 (en) 2011-04-20
CA2776964C (en) 2019-03-05
WO2011042501A2 (en) 2011-04-14
CA2776964A1 (en) 2011-04-14
DK2485756T3 (en) 2015-06-08
JP5801814B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
US6592863B2 (en) Nutritional composition
US8178487B2 (en) Method for providing glutamine
CN100352374C (zh) 引发过饱的组合物
EP1675480B1 (en) Nutritional composition against side effects of chemotherapy of radiotherapy
CN100353866C (zh) 用含亮氨酸的制剂刺激体内蛋白质的产生
RU2445955C1 (ru) Дикарбоновые кислоты со средней длиной цепи, их производные и метаболические нарушения
CN1649644A (zh) 用奶矿物质和酪蛋白组分治疗体重异常的组合物和方法
JP2006503105A (ja) ロイシンに富んだ栄養的組成物
CN102711803B (zh) 用于肠和肌肉恢复的glp‑2
RU2385647C2 (ru) Питание для пациентов, страдающих ожирением
KR20080049330A (ko) 포만감을 증가시키는 식품 조성물
US20100035810A1 (en) Adiponectin production enhancer
CN101242748A (zh) 含有蛋白酶抑制剂的婴儿营养品
JPS61215323A (ja) 栄養補給飲食品
AU2016348517B2 (en) Method for inducing satiety
US20070128252A1 (en) Compositions and methods for treatment of body weight conditions
HK1173949B (en) Glp-2 for use in the treatment of muscle atrophy
HK1039729B (en) Method for providing glutamine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191122

Address after: Vevey

Co-patentee after: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)

Patentee after: Societe des Produits Nestle S.A.

Address before: Vevey

Co-patentee before: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)

Patentee before: Nestle Products Technical Assistance Co.,Ltd.

TR01 Transfer of patent right
CP01 Change in the name or title of a patent holder

Address after: Vevey

Patentee after: Societe des Produits Nestle S.A.

Patentee after: National Institute of agriculture, food and environment

Address before: Vevey

Patentee before: Societe des Produits Nestle S.A.

Patentee before: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20250421

Address after: Vevey

Patentee after: Societe des Produits Nestle S.A.

Country or region after: Switzerland

Address before: Vevey

Patentee before: Societe des Produits Nestle S.A.

Country or region before: Switzerland

Patentee before: National Institute of agriculture, food and environment

Country or region before: France

TR01 Transfer of patent right